| Previous Close | 1.61 |
| Open | 1.62 |
| Day High | 1.64 |
| Day Low | 1.55 |
| 52-Week High | 3.27 |
| 52-Week Low | 1.18 |
| Volume | 8,240 |
| Average Volume | 17,300 |
| Market Cap | 66.41M |
| PE | -6.73 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 1.71 |
| Change | 0.01 |
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
GlobeNewswire Inc.
Feb 09, 2026 12:15 PM GMT
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in th
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec.
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent sur